Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.


AIMS The demonstration that endothelin production is upregulated in pulmonary artery hypertension (PAH) served as the rationale for developing endothelin-receptor antagonists (ERAs) as a treatment for PAH. This article reviews the primary studies demonstrating efficacy of ERAs in PAH. MAIN METHODS Multicenter, placebo-controlled trials and open-label… (More)
DOI: 10.1016/j.lfs.2012.07.033


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics